References
- Borgers M, De Nollin S, Thone F, van Belle H. Cytochemical localization of NADH oxidase in Candida albicans.J. Histochem. Cytochem.25(3), 193–199 (1977).
- Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin. Microbiol. Rev.12, 40–79 (1999).
- Van den Bossche H, Willemsens G, Marichal P. Anti-Candida drugs – the biochemical basis for their activity.Crit. Rev. Microbio.15, 57–72 (1987).
- Van den Bossche H. Biochemical effects of miconazole on fungi: effects of the uptake and/or utilization of purines, pyrimidines, nucleosides, amino acids and glucose by Candida albicans.Biochem. Pharmacol.23(4), 887–899 (1974).
- Boschman CR, Bodnar UR, Tornatore MA et al. Thirteen-year evolution of azole resistance in yeast isolates and prevalence of resistant strains carried by cancer patients at a large medical center. Anti microb. Agents Chemother.42, 734–738 (1998).
- Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. Antifungal susceptibilies of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J. Clin. Microbiol.43, 2155–2162 (2005).
- Walsh TJ, Pizzo A. Treatment of systemic fungal infections: recent progress and current problems. Eur. J. Clin. Microbiol. Infect. Dis.7(4), 460–467 (1988).
- Walsh TJ, Newman KR, Moody M, Wharton RC, Wade JC. Trichosporonosis in patients with neoplastic disease. Medicine65(4), 268–279 (1986).
- King CT, Rogers PD, Cleary JD, Chapman SW. Antifungal therapy during pregnancy. Clin. Infect. Dis.27, 1151–1158 (1998).
- Czeizel AE, Kazy Z, Puho E. Population-based case-control teratologic study of topical miconazole. Congenit. Anom.44, 41–45 (2003).
- Kazy K, Puho E, Cueizel AE. The possible association between the combination of vaginal metronidazole and miconazole treatment and poly–syndactyly population-based case-control teratologic study. Reprod. Toxicol.20, 89–94 (2005).
- Georgopapadakou NH. Antifungals: mechanism of action and resistance, established and novel drugs. Curr. Opin. Microbiol.1, 547–557 (1998).
- Jain P, Akula I, Edlind T. Cyclic AMP signaling pathway modulates susceptibility of Candida species and Saccharomyces cerevisiae to antifungal azoles and other sterol biosynthesis inhibitors. Antimicrob. Agents Chemother.47, 3195–3201 (2003).
- White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev.11, 382–402 (1998).
- Dorrell L, Edwards A. Vulvovaginitis due to fluconazole resistant Candida albicans following self treatment with non-prescribed triazoles. Sex. Transm. Infect.78(4), 308–309 (2002).
- De Nollin S, Borgers M. An ultrastructure and cytochemical study of Candida albicans after in vitro treatment with imidazoles. Mykosen19(9), 317–328 (1977).
- De Nollin S, van Belle H, Goossens F, Thone F, Borgersm M. Cytochemical and biochemical studies of yeasts after in vitro exposure to miconazole. Antimicrob. Agents. Chemother.11(3), 500–513 (1977).
- Kobayashi DK, Kondo Uehara N, Otokozawa S, Tsuji N, Yagihashi A, Watanabe N. Endogenous reactive oxygen species is an important mediator of miconazole antifungal effect. Antimicrob. Agents. Chemother.46(10), 3113–3117 (2002).